Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 16

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 16
---
 also obtain these documents by requesting them via e-mail from IRAA@allianceadvisors.com.

If you are a stockholder of Iris and would like to request documents, please do so by February 25, 2025 (which is five business days prior to the date of the Special Meeting), in order to receive them before the Special Meeting. If you request any documents from us, we will mail them to you by first class mail, or another equally prompt means.

TABLE OF CONTENTS

### EXPLANATORY NOTE
On November 8, 2023, Iris Parent Holding Corp., a Delaware corporation (“ParentCo”), filed a registration statement with the Securities and Exchange Commission (the “SEC”), on Form S-4 (File No. 333-275409) of which this proxy statement/prospectus forms a part (as amended, the “Registration Statement”). The Registration Statement was initially declared effective by the SEC on August 9, 2024. On August 16, 2024, Liminatus Pharma, LLC (“Liminatus”) informed us that Targeted Diagnostics & Therapeutics, Inc. (“TDT”), Liminatus’s license partner for the intellectual property and other rights related to GCC (CAR-T therapy and cancer vaccine), terminated the License and Development Agreement, dated June 10, 2018, by and between TDT and Liminatus (the “TDT License Termination”). TDT asserted that the termination was due to Liminatus’ failure to make the milestone payments under the agreement, but Liminatus believes it was current on the milestone payments. TDT has not communicated further since terminating the license. Following the receipt of the termination notice, and after considering the development status of the CAR-T products, Liminatus management concluded, in its business judgment, that notwithstanding the loss of the license from TDT and considering the pre-clinical advancement and market potential of its CD47 asset, to proceed with its business plan without the license from TDT.

We filed post-effective amendments to the Registration Statement to update the Registration Statement to: (i) include the information contained in Iris Acquisition Corp’s Quarterly Report on Form 10- Q for the quarterly period ended September 30, 2024, filed with the SEC on November 27, 2024, and the financial information of Liminatus as of and for the period ended September 30, 2024, (ii) update the unaudited pro forma combined financial information contained in the